ReviewBiological psychiatry2021
The β-Secretase BACE1 in Alzheimer's Disease.
Open access · bronzeAbstract readReview
In one paragraph
Review in Biological psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 353 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
353citing papers in PubMed, 2 pooled it
38.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
353 citing papers in PubMed, 2 syntheses or guidelines pooled it, 633 citations in OpenAlex.
- Long non-coding RNAs in glial cells: key drivers of neuroinflammation in cognitive disorders.Frontiers in aging neuroscience · 2026Pooled it
- The Effects and Mechanisms of Xanthones in Alzheimer's Disease: A Systematic Review.Neurochemical research · 2023Pooled it
- Bergamottin pretreatment attenuates cisplatin-induced acute kidney injury in mice by inhibiting BACE-1-mediated ferroptosis.Renal failure · 2026Article
- lncRNAs: key player in Aβ deposition.RNA biology · 2026Review
- Blood-based biomarkers and early diagnosis of Alzheimer's disease.Neural regeneration research · 2026Article
- Transcriptomic Signatures of Microglial Phagocytosis Reveal Diagnostic Markers and Immune Landscape in Alzheimer's Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Plasma Concentrations of Amyloid-β Peptides, BACE-1, and Tau Proteins in Alzheimer's Disease.Turkish journal of pharmaceutical sciences · 2026Article
- The role of SUMOylation in regulating proteins that drive neuronal disease progression.Biochemistry and biophysics reports · 2026Review
- Effects of BACE2 polymorphisms on verbal memory in the general population.European archives of psychiatry and clinical neuroscience · 2026Article
- Neurodegenerative diseases and immune system: From pathogenic mechanism to therapy.Neural regeneration research · 2026Article
- 2-(Arylamino)thiazol-4(5H)-ones Mitigate Oxidative Stress and Confer Neuroprotection in Cellular andInternational journal of molecular sciences · 2026Article
- Epigenetic Mechanisms of Vitamin D in the Aging Process: A Narrative Review.International journal of molecular sciences · 2026Review
- Development of a Novel AAV-Mediated microRNA Gene Therapy for Spatial Suppression of BACE1 to Improve Cognitive Function in Alzheimer's Disease Model Mice.Biomolecules · 2026Article
- Article
- Could the cognitive benefits of amyloid-beta clearance grow in time for Alzheimer's disease?Translational psychiatry · 2026Review
- Tetrapeptide inhibitors of BACE-1 revealed by combined data-driven screening and physics-based free-energy refinement.Molecular diversity · 2026Article
- The short-chain fatty acid butyrate prevents gut-brain amyloid-β pathology and neuroinflammation in an Alzheimer mouse model.Molecular psychiatry · 2026Article
- Achieving protease substrate-specific inhibition by mAb dual functional selections.Protein science : a publication of the Protein Society · 2026Article
- Structure-Guided Discovery of a Nonpeptidic MT5-MMP Inhibitor.ACS medicinal chemistry letters · 2026Article
- Licochalcone a enhances cognitive resilience in APP/PS1 Mice by modulating glucose metabolism, Aβ burden, and neuroinflammation.GeroScience · 2026Article
293 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 15 institutions in 8 countries.
Harald HampelNeurology Business Group, Eisai Inc., Woodcliff Lake, New Jersey; Sorbonne University, GRC No. 21, Alzheimer Precision Medicine, Pitié-Salpêtrière Hospital, Paris, France. Electronic address: harald_hampel@eisai.com.
Robert VassarDepartment of Neurology, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Bart De StrooperDepartment of Neurosciences, KU Leuven, Leuven, Belgium; Centre for Brain and Disease Research, VIB (Flanders Institute for Biotechnology), Leuven, Belgium; Dementia Research Institute, University College London, London, United Kingdom.
John HardyDepartment of Molecular Neuroscience and Reta Lilla Weston Laboratories, Queen Square Institute of Neurology, University College London, London, United Kingdom.
Michael WillemChair of Metabolic Biochemistry, Biomedical Center, Faculty of Medicine, Ludwig Maximilians University Munich, Munich, Germany.
Neeraj SinghDepartment of Neuroscience, University of Connecticut Health, Farmington, Connecticut.
John ZhouDepartment of Neuroscience, University of Connecticut Health, Farmington, Connecticut.
Riqiang YanDepartment of Neuroscience, University of Connecticut Health, Farmington, Connecticut.
Eugeen VanmechelenADx NeuroSciences NV, Ghent, Belgium.
Ann De VosADx NeuroSciences NV, Ghent, Belgium.
Robert NisticòLaboratory of Neuropharmacology, EBRI Rita Levi-Montalcini Foundation, Rome, Italy; School of Pharmacy, Department of Biology, University of Rome "Tor Vergata," Rome, Italy.
Massimo CorboDepartment of Neurorehabilitation Sciences, Casa Cura Policlinico, Milan, Italy.
Bruno Pietro ImbimboDepartment of Research and Development, Chiesi Farmaceutici, Parma, Italy.
Johannes StrefferReference Center for Biological Markers of Dementia, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; UCB Biopharma SPRL, Braine-l'Alleud, Belgium.
Iryna VoytyukDepartment of Neurosciences, KU Leuven, Leuven, Belgium; Centre for Brain and Disease Research, VIB (Flanders Institute for Biotechnology), Leuven, Belgium; ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge, United Kingdom.
Maarten TimmersReference Center for Biological Markers of Dementia, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Janssen Research and Development, a division of Janssen Pharmaceutica, Beerse, Belgium.
Amir Abbas Tahami MonfaredNeurology Business Group, Eisai Inc., Woodcliff Lake, New Jersey; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
Michael IrizarryNeurology Business Group, Eisai Inc., Woodcliff Lake, New Jersey.
Bruce AlbalaNeurology Business Group, Eisai Inc., Woodcliff Lake, New Jersey.
Akihiko KoyamaNeurology Business Group, Eisai Inc., Woodcliff Lake, New Jersey.
Naoto WatanabeEisai Company Ltd., Tokyo, Japan.
Teiji KimuraEisai Company Ltd., Tokyo, Japan.
Lisa YarenisNeurology Business Group, Eisai Inc., Woodcliff Lake, New Jersey.
Simone ListaSorbonne University, GRC No. 21, Alzheimer Precision Medicine, Pitié-Salpêtrière Hospital, Paris, France; Institute of Memory and Alzheimer's Disease, Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France; Brain & Spine Institute, INSERM U 1127, CNRS UMR 7225, Paris, France.
Lynn KramerNeurology Business Group, Eisai Inc., Woodcliff Lake, New Jersey.
Andrea VergalloNeurology Business Group, Eisai Inc., Woodcliff Lake, New Jersey; Sorbonne University, GRC No. 21, Alzheimer Precision Medicine, Pitié-Salpêtrière Hospital, Paris, France; Institute of Memory and Alzheimer's Disease, Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France; Brain & Spine Institute, INSERM U 1127, CNRS UMR 7225, Paris, France. Electronic address: andrea_vergallo@eisai.com.
Eisai (United States) · USUConn Health · USADx NeuroSciences · BECentre National de la Recherche Scientifique · FREisai (Japan) · JPChiesi (Italy) · ITJanssen (Belgium) · BELudwig-Maximilians-Universität München · DENational Hospital for Neurology and Neurosurgery · GBNorthwestern University · USSorbonne Université · FRUniversity of Antwerp · BEUniversity of Cambridge · GBUniversity of Rome Tor Vergata · ITVlaams Instituut voor Biotechnologie · BE
Funding
Supplement for BACE1 in neurodegeneration and neuronal dysfunctionR01NS074256 · NINDS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI RIQIANG YAN · 2011 to 2026
$5.8MInhibition of BACE1 for benefiting Alzheimer's patientsRF1AG046929 · NIA · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI YAN, RIQIANG · 2018 to 2018
$3.3MMedical Research Council G0701075Medical Research Council G0901254Medical Research Council MR/L501542/1Medical Research Council MR/N026004/1NIA NIH HHS RF1 AG046929NINDS NIH HHS R01 NS074256Parkinson's UK G-0907
Abstract
BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) was initially cloned and characterized in 1999. It is required for the generation of all monomeric forms of amyloid-β (Aβ), including Aβ
Indexed as
Alzheimer DiseaseAmyloid Precursor Protein SecretasesAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsAspartic Acid EndopeptidasesHumansMiceMice, KnockoutAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAmyloid Precursor Protein SecretasesAspartic Acid EndopeptidasesBACE1 protein, humanBace1 protein, mouseBace2 protein, mouseAlzheimer’s diseaseBACE1 inhibitorsBiomarkersClinical trialsSoluble amyloidSynaptic
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.